# APBA Kısa Özet

This meta-analysis evaluated the effects of a specific multinutrient intervention on cognitive function across the stages of Alzheimer's disease. Data from three randomized, placebo-controlled trials (total n = 906) yielded a standardized mean difference (SMD) of 0.08 (95% CI, -0.09 to 0.26), which was not statistically significant (p = 0.35). While the overall effect was null, exploratory subgroup analyses suggested a possible signal in earlier disease stages. A 36-month extension of the LipiDiDiet trial reported significant differences in cognition, clinical dementia rating, memory, and brain volume outcomes, but these findings are limited to a single study.

# Çalışma neyi araştırdı?

Researchers aimed to investigate the effects of a specific multinutrient intervention, which provides precursors and cofactors for synaptic membrane synthesis, on cognitive function across the Alzheimer's disease continuum. The study assumed that disease stage could act as an effect modifier and conducted a stage-stratified meta-analysis. Databases including MEDLINE, Embase, CENTRAL, Web of Science, Scopus, ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform were searched through February 28, 2026.

Inclusion criteria required randomized, double-blind, placebo-controlled trials with a diagnosis of Alzheimer's disease (clinically or biomarker-supported) and utilization of the specific multinutrient intervention. Exclusion criteria encompassed non-randomized designs, non-Alzheimer populations, and interventions lacking the specified nutrient profile.

# Yöntem

  • Arama stratejisi: Comprehensive literature searches were performed in MEDLINE, Embase, CENTRAL, Web of Science, Scopus, ClinicalTrials.gov, and the WHO ICTRP up to February 28, 2026.
  • Dahil etme kriterleri: Randomized, double-blind, placebo-controlled trials; Alzheimer's disease diagnosis (clinical or biomarker-supported); intervention with the specific multinutrient.
  • Veri çıkarımı: Standardized mean differences (SMD; Hedges' g) were calculated for each trial's cognitive outcome.
  • İstatistiksel model: A restricted maximum likelihood (REML) random-effects model was used to synthesize SMDs across trials. Heterogeneity was assessed using the I² statistic.
  • Alt‑grup analizleri: Pre-specified subgroup analyses examined effects by disease stage (prodromal vs. mild-to-moderate) and follow-up duration (e.g., 36-month extension).

# Temel bulgular

  • Kapsam: Four trials were identified for inclusion; however, only three contributed to the quantitative synthesis (analyzed n = 906). The fourth trial (Souvenir I) was retained for qualitative synthesis due to distinct co-primary outcomes that precluded compatible SMD calculation.
  • Genel pooled effect: The exploratory pooled cognitive effect was small and not statistically significant (SMD = 0.08; 95% CI, -0.09 to 0.26; p = 0.35; I² = 41.8%).
  • Prodromal Alzheimer's disease (biomarker-confirmed): The 24-month primary neuropsychological test battery (NTB) 5-item composite endpoint showed a small, non-significant effect (SMD = 0.16; 95% CI, -0.08 to 0.41; original trial p = 0.166).
  • Mild-to-moderate Alzheimer's disease: The primary Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) endpoint in treated patients showed no benefit (SMD = -0.06; 95% CI, -0.25 to 0.13; p = 0.513).
  • 36-month extension (LipiDiDiet): At 36 months, the extension reported significant differences in the NTB 5-item composite, clinical dementia rating - sum of boxes (CDR-SB), memory, and brain-volume outcomes; however, these results derive from a single extension study.

# Bulgular ne anlama geliyor?

Overall, the current evidence does not support a clinically meaningful cognitive benefit of the multinutrient intervention for Alzheimer's disease patients as a whole. The small, positive SMD observed in the prodromal subgroup suggests a potential signal for efficacy in earlier disease stages, but this finding is not statistically robust and requires cautious interpretation. The significant findings from the 36-month LipiDiDiet extension, while notable, are based on a single study and cannot be generalized to broader populations or longer-term effects with confidence.

# Klinik önem

APBA interprets these findings as follows: Routine clinical implementation of the multinutrient intervention to improve cognitive function in Alzheimer's disease is not supported by the current evidence base. The limited data, potential commercial bias due to manufacturer sponsorship, and inconsistent cognitive endpoints across studies hinder definitive conclusions. However, the exploratory signal in prodromal AD warrants further investigation with larger, independent trials using homogeneous cognitive batteries. Clinical decisions should acknowledge the paucity of data and the presence of possible conflicts of interest.

# Sınırlılıklar

  • Küçük kanıt tabanı: Only three randomized trials (n = 906) were included in the quantitative synthesis. This limited evidence base restricts the statistical power and generalizability of the results.
  • Heterojen ölçütler: Included trials utilized diverse cognitive assessment batteries (e.g., ADAS-Cog, NTB composites) and targeted different Alzheimer's disease stages, complicating direct comparison and uniform pooling.
  • Ticari bias: Some of the included trials were sponsored by the multinutrient manufacturer, raising the possibility of commercial bias influencing study design, execution, or reporting.
  • Uzun vadeli veri eksikliği: The 36-month extension findings are based on a single study; therefore, the generalizability of long-term effects remains uncertain.
  • Biyobelirteç doğrulaması: The prodromal AD subgroup analysis was limited to biomarker-confirmed (amyloid/PET) participants; biomarker validation was absent in other subgroups, potentially affecting the specificity of stage-stratified effects.

APBA emphasizes that the current evidence is insufficient to support routine clinical use of the multinutrient intervention for Alzheimer's disease. Robust conclusions will require larger, multicenter, independently funded trials with standardized cognitive outcomes and rigorous methodological standards.